Cone-Rod Dystrophy clinical trials at UCSF
2 research studies open to eligible people
Cone-rod dystrophy is an inherited retinal condition that reduces color and night vision. UCSF is collecting detailed eye images ahead of human cone optogenetics studies. UCSF is also running an early phase study testing rising doses of a new ABCA4 therapy.
ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
open to eligible people ages 12 years and up
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
San Francisco, California and other locations
EyeConic: Qualification for Cone-Optogenetics
open to all eligible people
This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.
San Francisco, California and other locations
Our lead scientists for Cone-Rod Dystrophy research studies include Jacque Duncan.
Last updated: